文献速递心脑血管急症

非侵入性心脏检查与单纯临床评估在急性胸痛中的比较:ROMICAT-II随机临床试验的二次分析

Noninvasive Cardiac Testing vs Clinical Evaluation Alone in Acute Chest Pain: A Secondary Analysis of the ROMICAT-II Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2018-01-01
一句话结论在急性胸痛、生物标志物阴性且心电图无缺血表现的患者中,非侵入性检查(CCTA或负荷试验)较单纯临床评估延长住院时间、增加下游检查和辐射暴露及费用,而未改善临床结局。

本研究为ROMICAT-II随机对照试验的回顾性二次分析,纳入美国9家医院急诊科1000例急性胸痛患者。比较临床评估联合非侵入性检查(CCTA或负荷试验)与单纯临床评估。结果显示,未接受非侵入性检查的患者住院时间更短(20.3 vs 27.9小时,P<0.001),诊断性检查率和血管造影率更低(2% vs 11%,P<0.001),中位费用更低(2261.50 vs 2584.30美元,P=0.009),累积辐射暴露更少(0 vs 9.9 mSv,P<0.001)。28天随访中,两组经皮冠状动脉介入治疗(PCI)、冠状动脉旁路移植术、再次急诊就诊或主要不良心脏事件(MACE)发生率无显著差异。结论认为,在该人群中,非侵入性检查未改善临床结局。

要点

  • 在急诊胸痛、生物标志物阴性且心电图无缺血表现的患者中,非侵入性检查(CCTA或负荷试验)组住院时间较单纯临床评估组延长(27.9 vs 20.3小时,P<0.001)。
  • 非侵入性检查组血管造影率高于单纯临床评估组(11% vs 2%,P<0.001),但28天PCI率无显著差异(5% vs 2%,P=0.15)。
  • 非侵入性检查组累积辐射暴露高于单纯临床评估组(9.9 vs 0 mSv,P<0.001),中位费用也更高(2584.30 vs 2261.50美元,P=0.009)。
  • 28天随访中,非侵入性检查组与单纯临床评估组的MACE发生率无显著差异(1% vs 2%,P=0.24),再次急诊就诊率也无显著差异(2.8% vs 5.8%,P=0.08)。
  • 单纯临床评估组未诊断出急性冠脉综合征(0% vs 9%,P<0.001),但该差异与检查策略相关,需结合安全性终点解读。

适用人群与场景

  • 美国9家医院急诊科就诊的急性胸痛患者,来自ROMICAT-II随机对照试验的1000例患者。
  • 纳入标准隐含为急性胸痛、生物标志物阴性且心电图无缺血表现(基于结论部分描述)。

研究设计与关键结果

  • 研究类型:ROMICAT-II随机对照试验的回顾性二次分析,纳入美国9家医院急诊科的1000例急性胸痛患者。
  • 干预与对照:临床评估联合非侵入性检查(CCTA或负荷试验) vs 单纯临床评估;118例(12%)未接受非侵入性检查,882例(88%)接受了CCTA或负荷试验。
  • 主要终点:住院时间,非侵入性检查组27.9小时 vs 单纯临床评估组20.3小时(P<0.001)。
  • 关键次要终点:血管造影率非侵入性检查组11% vs 单纯临床评估组2%(P<0.001);中位费用2584.30美元 vs 2261.50美元(P=0.009);累积辐射暴露9.9 mSv vs 0 mSv(P<0.001)。
  • 28天随访:PCI率非侵入性检查组5% vs 单纯临床评估组2%(P=0.15);冠状动脉旁路移植术率1% vs 0%(P=0.61);再次急诊就诊率2.8% vs 5.8%(P=0.08);MACE发生率1% vs 2%(P=0.24),均无显著差异。
  • 索引就诊期间:急性冠脉综合征诊断率非侵入性检查组9% vs 单纯临床评估组0%(P<0.001);冠状动脉造影率10% vs 0%(P<0.001);PCI率4% vs 0%(P=0.02)。

证据类型、等级与局限

  • 证据类型:随机对照试验(ROMICAT-II)的回顾性二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急诊胸痛、生物标志物阴性且心电图无缺血表现的患者,采用CCTA或负荷试验的非侵入性检查策略较单纯临床评估延长住院时间、增加下游检查、辐射暴露和费用,而未改善28天临床结局(MACE、PCI、再次急诊就诊无显著差异)。
  • 单纯临床评估组未诊断出急性冠脉综合征(0% vs 9%),作者结论认为非侵入性检查未改善临床结局,但该差异需结合安全性终点解读。

指南或共识出处

  • ROMICAT-II随机对照试验(clinicaltrials.gov Identifier: NCT01084239)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The incremental benefit of noninvasive testing in addition to clinical evaluation (history, physical examination, an electrocardiogram [ECG], and biomarker assessment) vs clinical evaluation alone for patients who present to the emergency department (ED) with acute chest pain is unknown.

OBJECTIVE: To examine differences in outcomes with clinical evaluation and noninvasive testing (coronary computed tomographic angiography [CCTA] or stress testing) vs clinical evaluation alone.

DESIGN, SETTING, AND PARTICIPANTS: This study was a retrospective analysis of data from the randomized multicenter Rule Out Myocardial Ischemia/Infarction by Computer Assisted Tomography (ROMICAT-II) trial. Data for 1000 patients who presented with chest pain to the EDs at 9 hospitals in the United States were evaluated.

INTERVENTIONS: Clinical evaluation plus noninvasive testing (CCTA or stress test) vs clinical evaluation alone.

MAIN OUTCOMES AND MEASURES: Primary outcome was length of stay (LOS). Secondary outcomes included hospital admission, direct ED discharge, downstream testing, rates of invasive coronary angiography, revascularization, major adverse cardiac events (MACE), repeated ED visit or hospitalization for recurrent chest pain at 28 days, and cost. Safety end points were missed acute coronary syndrome (ACS) and cumulative radiation exposure during the index visit and follow-up period.

RESULTS: Of the 1000 patients randomized, 118 patients (12%) (mean [SD] age, 53.2 [7.8]; 49 [42%] were female) did not undergo noninvasive testing, whereas 882 (88%) (mean [SD] age, 54.4 [8.14] years; 419 [48%] were female) received CCTA or stress testing. There was no difference in baseline characteristics or clinical presentation between groups. Patients who underwent clinical evaluation alone experienced a shorter LOS (20.3 vs 27.9 hours; P < .001), lower rates of diagnostic testing (P < .001) and angiography (2% vs 11%; P < .001), lower median costs ($2261.50 vs $2584.30; P = .009), and less cumulative radiation exposure (0 vs 9.9 mSv; P < .001) during the 28-day study period. Lack of testing was associated with a lower rate of diagnosis of ACS (0% vs 9%; P < .001) and less coronary angiography and percutaneous coronary intervention (PCI) during the index visit (0% vs 10%; P < .001, and 0% vs 4%; P = .02, respectively). There was no difference in rates of PCI (2% vs 5%; P = .15), coronary artery bypass surgery (0% vs 1%; P = .61), return ED visits (5.8% vs 2.8%; P = .08), or MACE (2% vs 1%; P = .24) in the 28-day follow-up period.

CONCLUSIONS AND RELEVANCE: In patients presenting to the ED with acute chest pain, negative biomarkers, and a nonischemic ECG result, noninvasive testing with CCTA or stress testing leads to longer LOS, more downstream testing, more radiation exposure, and greater cost without an improvement in clinical outcomes.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01084239.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Reinhardt SW, Lin CJ, Novak E, et al. Noninvasive Cardiac Testing vs Clinical Evaluation Alone in Acute Chest Pain: A Secondary Analysis of the ROMICAT-II Randomized Clinical Trial. JAMA Intern Med. 2018. PMID: 29138794. doi:10.1001/jamainternmed.2017.7360

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。